A Phase I Study of ALKS 4230 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2018
At a glance
- Drugs ALKS 4230 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Alkermes plc
- 14 Feb 2018 According to an Alkermes media release, dose escalation data and dose expansion initiation is anticipated in H2 2018.
- 02 Feb 2018 Planned number of patients changed from 120 to 130.
- 02 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.